Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Standard-of-care treatment for TNBC includes ...

NBCUniversal's free, ad-supported streaming television channel TNBC is getting a rebrand. Starting on June 1, the FAST offering will be known as NBC Comedy Vault and will be available on Amazon ...